Abstract:Background: Pharmacogenomics (PGx) aims to utilize a patient's genetic data to enable safer and more effective prescribing of medications. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines with strong evidence for 24 genes that affect 72 medications. Despite strong evidence linking PGx alleles to drug response, there is a large gap in the implementation and return of actionable pharmacogenetic findings to patients in standard clinical practice. In this study, we evaluated opportunities for genetically guided medication prescribing in a diverse health system and determined the frequencies of actionable PGx alleles in an ancestrally diverse biobank population. Methods: A retrospective analysis of the Penn Medicine electronic health records (EHRs), which includes ~ 3.3 million patients between 2012 and 2020, provides a snapshot of the trends in prescriptions for drugs with genotype-based prescribing guidelines ('CPIC level A or B') in the Penn Medicine health system. The Penn Medicine BioBank (PMBB) consists of a diverse group of 43,359 participants whose EHRs are linked to genome-wide SNP array and whole exome sequencing (WES) data. We used the Pharmacogenomics Clinical Annotation Tool (PharmCAT), to annotate PGx alleles from PMBB variant call format (VCF) files and identify samples with actionable PGx alleles. Results: We identified ~ 316.000 unique patients that were prescribed at least 2 drugs with CPIC Level A or B guidelines. Genetic analysis in PMBB identified that 98.9% of participants carry one or more PGx actionable alleles where treatment modification would be recommended. After linking the genetic data with prescription data from the EHR, 14.2% of participants (n = 6157) were prescribed medications that could be impacted by their genotype (as indicated by their PharmCAT report). For example, 856 participants received clopidogrel who carried CYP2C19 reduced function alleles, placing them at increased risk for major adverse cardiovascular events. When we stratified by genetic ancestry, we found disparities in PGx allele frequencies and clinical burden. Clopidogrel users of Asian ancestry in PMBB had significantly higher rates of CYP2C19 actionable alleles than European ancestry users of clopidrogrel (p < 0.0001, OR = 3.68). Conclusions: Clinically actionable PGx alleles are highly prevalent in our health system and many patients were prescribed medications that could be affected by PGx alleles. These results illustrate the potential utility of preemptive genotyping for tailoring of medications and implementation of PGx into routine clinical care.

Genetic ancestry plays a central role in population pharmacogenomics

Increased Genetic Diversity of ADME Genes in African Americans Compared with Their Putative Ancestral Source Populations and Implications for Pharmacogenomics

Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences

Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population

Ancestry inference using principal component analysis and spatial analysis: a distance-based analysis to account for population substructure

A geographic history of human genetic ancestry

Pharmacogenomics in the Age of GWAS, Omics Atlases, and PheWAS

Characterizing the genetic architecture of drug response using gene-context interaction methods

SNVstory: inferring genetic ancestry from genome sequencing data

Pharmacogenomics in Precision Medicine: From a Perspective of Ethnic Differences

Improving genetic risk prediction across diverse population by disentangling ancestry representations

Discerning the Ancestry of European Americans in Genetic Association Studies

Linkage Disequilibrium and Haplotype Architecture for Two ABC Transporter Genes (ABCC1 and ABCG2) in Chinese Population: Implications for Pharmacogenomic Association Studies

The use of single-nucleotide polymorphism maps in pharmacogenomics

Novel probabilistic models of spatial genetic ancestry with applications to stratification correction in genome-wide association studies

A comprehensive framework for trans-ancestry pathway analysis using GWAS summary data from diverse populations

Analysis of East Asia genetic substructure using genome-wide SNP arrays

Genetic architectures of ADME genes in five Eurasian admixed populations and implications for drug safety and efficacy.

Impact of admixture and ancestry on eQTL analysis and GWAS colocalization in GTEx

The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data